Ignite Creation Date:
2024-05-05 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00428909
Status:
COMPLETED
Last Update Posted:
2016-04-21
First Post:
2007-01-29
Brief Title:
Effect of Imatinib Mesylate and the Pharmacokinetics of AcetaminophenParacetamol in Patients With Newly Diagnosed Previously Untreated Chronic Myeloid Leukemia in Chronic Phase CML-CP
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Non-randomized Open-label Study to Investigate the Effects of Imatinib Mesylate on the Pharmacokinetics of AcetaminophenParacetamol in Patients With Newly Diagnosed Previously Untreated Chronic Myeloid Leukemia in Chronic Phase CML-CP
Status:
COMPLETED
Status Verified Date:
2016-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A non-randomized open-label study to investigate the effects of imatinib mesylate on the pharmacokinetics of acetaminophenparacetamol in patients with newly diagnosed previously untreated chronic myeloid leukemia in chronic phase CML-CP
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None